Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexMale
Age18-90
SponsorAnhui Provincial Hospital
About this trial
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[18F\]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \[18F\]F-PSMA-1007.
Eligibility criteria
Qualifiers
Aged from 18 to 90 years old;
Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.);
Prostate cancer detected by PSA or imaging examination, or clinically suspected recurrence after standardized treatment;
simultaneous [18F]F-PSMA-N5 and [18F]F-PSMA-1007 examinations within two weeks;
Disqualifiers
Patients who cannot cooperate with the examination;
Concurrent malignant tumors;
Previous alcohol allergy;
Patients with liver and kidney dysfunction;
Trial design
Treatments tested in this trial
- [18F]F-PSMA-N5
- [18F]F-PSMA-1007
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov